Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study
Journal of Clinical Oncology · 2025-08 · 43 (22) · 2461-2466
DOI: 10.1200/jco-25-00183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-08. Verfasst von Adèle de Masson und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Hematopoietic Stem Cell Transplantation, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.
- INSERM U1342 Institut de Recherche Saint-Louis, Paris, France.
- Université Paris Cité, Paris, France.
- Department of Dermatology, CHU de Bordeaux, Bordeaux, France.
- INSERM U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France.
- Department of Hematology, L'Hôpital Pontchaillou, CHU de Rennes, Rennes, France.
ORCID-Profile: Adèle de Masson, Marie Beylot-Barry, Corentin Orvain, Olivier Dereure, Stéphane Barete, François Aubin, Roch Houot, David Michonneau, Hélène Labussière-Wallet, Hélène Moins-Teisserenc, Maxime Battistella, Etienne Daguindau, Michael Loschi, Anne Huynh, Ambroise Marçais, Sébastien Maury, Emmanuel Bachy, Edouard Forcade, Martine Bagot, Sylvie Chevret, Régis Peffault de Latour
Zitieren
APA
de Masson, A., Beylot-Barry, M., Ram-Wolff, C., Mear, J. B., Dalle, S., Rouanet, J., Ingen-Housz-Oro, S., Orvain, C., Abraham, J., Dereure, O., Charbonnier, A., Cornillon, J., Longvert, C., Barete, S., Boulinguez, S., Wierzbicka-Hainaut, E., Aubin, F., Rubio, M. T., Bernard, M., …, & CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire (2025). Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study. Journal of Clinical Oncology, 43(22), 2461-2466. https://doi.org/10.1200/jco-25-00183
Vancouver
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, Rouanet J, et al. Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study. Journal of Clinical Oncology. 2025;43(22):2461-2466. doi:10.1200/jco-25-00183
BibTeX
@article{deMasson2025,
author = {de Masson, Adèle and Beylot-Barry, Marie and Ram-Wolff, Caroline and Mear, Jean-Baptiste and Dalle, Stéphane and Rouanet, Jacques and Ingen-Housz-Oro, Saskia and Orvain, Corentin and Abraham, Julie and Dereure, Olivier and Charbonnier, Amandine and Cornillon, Jérôme and Longvert, Christine and Barete, Stéphane and Boulinguez, Serge and Wierzbicka-Hainaut, Ewa and Aubin, François and Rubio, Marie-Thérèse and Bernard, Marc and Schmidt-Tanguy, Aline and Houot, Roch and Pham-Ledard, Anne and Michonneau, David and Labussière-Wallet, Hélène and Bouaziz, Jean-David and Grange, Florent and Moins-Teisserenc, Hélène and Jondeau, Katayoun and Mourah, Samia and Battistella, Maxime and Daguindau, Etienne and Loschi, Michael and Picard, Alexandra and Franck, Nathalie and Maillard, Natacha and Huynh, Anne and Nguyen, Stéphanie and Marçais, Ambroise and Chaby, Guillaume and Ceballos, Patrice and Le Corre, Yannick and Maury, Sébastien and Bay, Jacques-Olivier and Adamski, Henri and Bachy, Emmanuel and Forcade, Edouard and Socié, Gérard and Bagot, Martine and Chevret, Sylvie and Peffault de Latour, Régis and CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire, CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire},
title = {Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {22},
pages = {2461--2466},
doi = {10.1200/jco-25-00183}
}
EUVIMED